Inc.'s eighth annual Female Founders list highlights the nation's top business leaders who challenge the status quo to tackle some of the world's biggest problems Pyx Health is proud to share that ...

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

PYX-201 is a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM), ...

The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC), PYX-201, to treat adults with recurrent or metastatic head and ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and ...

PYX-201 is a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago. These figures are ...

(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the ...

Pyxis Oncology, Inc. announced that the FDA has granted Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell ...